A Multicenter, Open-Label, Randomized, Active-Controlled, Parallel Group Chronic Safety Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease

NCT00064415 Phase 3 COMPLETED

The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD

Details

Lead sponsor	Sumitomo Pharma America, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	799
Start date	2002-06
Completion	2004-12

Conditions

• Chronic Obstructive Pulmonary Disease
• Chronic Bronchitis
• Emphysema

Interventions

• arformoterol
• Salmeterol

Primary outcomes

• Overall occurrence of adverse events — Weeks -1, 0, 3, 6, 9, 13, 26, 39, 52

Countries

United States